10. Conclusion

Though drug targeting to a specific site in the body is an interesting approach, it is a highly challenging task. Despite that a large variety of smart nanocarriers have been developed for drug targeting in recent years, SLN has achieved a special status among them and can be employed for both passive as well as active targeting. These can be

employed for delivering not only the drug but also antibody, proteins, genes, imaging agents etc. and bring about increased cellular uptake at the targeted disease sites. Moreover, surface modification of SLNs through conjugation of various ligands on SLNs surfaces helped in enhancing its targeting efficacy in terms of cellular binding, uptake and intracellular transport to different cells as well as organs and ensure its greatest potentiality to combat wide ranges of diseases. However, the intrinsic complexity of biological environments strongly influences its functionality and often complicates their effective use for therapeutic treatments. Therefore, a deeper knowledge and understanding of the real interactions involved in the diseased tissues is fundamental for the development of therapeutic protocols of SLNs.

GEL Gelucire®50/13

DOI: http://dx.doi.org/10.5772/intechopen.88268

GT glycerol trioleate GTP glyceryl tripalmitate GTS Glycerol tristearate HSC hepatic stellate cells IMC indomethacin LDL low density lipid LfR lactoferrin receptor Lf-SLN lactoferrin SLN KTZ ketoconazole

MR mannose receptor Msy-SLN mannosylated SLN

MTX methotrexate PA palmitic acid PC phosphatidylcholine PEG-SLN PEGylated SLNs PL phospholipid PL90NG Phospholipon 90NG PP primaquine phosphate

PRE Precirol ATO5

siRNA small interfering RNA SD Sprague-Dawley SP soybean phospholipid SPC soya phosphatidylcholine

TMP-I trimethylphytosphingosine-iodide

WGA-SLN wheat germ agglutinin conjugated SLN

strain (3D7)

3D7 asexual intraerythrocytic stage of P. falciparum laboratory

STA stearyl amine TD 1-tetradecanol TMC tobramycin TMP temoporfin

TMS trimyristin TP tripalmitate TSN tristearin VIN vinpocetine

117

PTX paclitaxel RIF rifampicin RFB rifabutin RSV resveratrol RLZ riluzole SA stearic acid SFB sorafenib SL soya lecithin SIA sialic acid

GMS glyceryl monostearate GS glyceryl stearate

G-SLNs galactosylated lipid conjugated SLNs

Solid Lipid Based Nano-particulate Formulations in Drug Targeting

MIC minimum inhibitory concentration

Mt. intercalated montmorillonite SLN

Mn (II) complex [Mn2(l (C6H5)2CHCOO)2(bipy)4](bipy)(ClO4)2 complex

POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine

GL glycerol
